Remarkable antibiofilm activity of ciprofloxacin, cefoxitin, and tobramycin, by themselves or in combination, against enteroaggregative Escherichia coli in vitro

Diagn Microbiol Infect Dis. 2023 Nov;107(3):116048. doi: 10.1016/j.diagmicrobio.2023.116048. Epub 2023 Aug 2.

Abstract

Enteroaggregative Escherichia coli (EAEC), a biofilm forming pathogen, causes acute and persistent diarrhea worldwide, requiring antimicrobial therapy in severe or persistent cases. To determine the susceptibility of EAEC biofilm to antimicrobials, as single-agent or combined therapy, biofilm formation was investigated using EAEC clinical strains via peg lid. Of the 78 initially analyzed strains, 35 could form biofilms, 15 (42.9%; 15/35) were resistant to at least 1 tested antimicrobial and 20 (57.1%) were susceptible to all of them in the planktonic form. The biofilms of these susceptible strains were challenged against chosen antimicrobials, and displayed resistance to tetracycline, trimethoprim-sulfamethoxazole, chloramphenicol, ampicillin, cefotaxime, ceftriaxone (85%-100%), tobramycin (25%), cefoxitin (20%), and ciprofloxacin (5%). Moreover, ciprofloxacin combined with ampicillin, and tobramycin eradicated the biofilm of 2 of the 4 tested strains. Ciprofloxacin, cefoxitin, and tobramycin maintained their activity well against EAEC biofilm, suggesting their possible effectiveness to treat diarrhea caused by biofilm-forming EAEC strains.

Keywords: Antimicrobial agents; Biofilm; Enteroaggregative Escherichia coli.

MeSH terms

  • Ampicillin
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Biofilms
  • Cefoxitin / pharmacology
  • Ciprofloxacin / pharmacology
  • Diarrhea
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli*
  • Humans
  • Tobramycin / pharmacology

Substances

  • Cefoxitin
  • Ciprofloxacin
  • Tobramycin
  • Anti-Bacterial Agents
  • Ampicillin